CASI Pharmaceuticals (CASIF) EBT (2022 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly EBT came in at -$77.5 million in Q4 2025, down 495.74% YoY from $19.6 million in Q4 2024, and down 626.99% on a QoQ basis from -$10.7 million in Q3 2025.
CASI Pharmaceuticals (CASIF) EBT (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 4 years of EBT data on file, last reported at -$77.5 million in Q4 2025.
- Quarterly EBT fell 495.74% year-over-year to -$77.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$109.6 million (down 178.77% YoY) and the FY2025 annual result came in at -$18.2 million, up 52.19% from the prior year.
- EBT retreated to -$77.5 million in Q4 2025, from -$10.7 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$5.1 million in Q3 2023 to a low of -$100.5 million in Q4 2022.
- A 4-year average of -$22.2 million and a median of -$9.3 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2024 — EBT jumped 79.88% — and 2025, when it slumped 495.74%.
- Tracing CASIF's EBT over 4 years: stood at -$100.5 million in 2022, then soared by 35.6% to -$64.7 million in 2023, then soared by 79.88% to -$13.0 million in 2024, then tumbled by 495.74% to -$77.5 million in 2025.
- The last three EBT figures came in at -$77.5 million (Q4 2025), -$10.7 million (Q3 2025), and -$11.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -77.55 Mn |
| Sep 30, 2025 | -10.67 Mn |
| Jun 30, 2025 | -11.08 Mn |
| Mar 31, 2025 | -10.30 Mn |
| Dec 31, 2024 | -13.02 Mn |
| Sep 30, 2024 | -8.32 Mn |
| Jun 30, 2024 | -8.65 Mn |
| Mar 31, 2024 | -9.32 Mn |
| Dec 31, 2023 | -64.71 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -9.35 Mn |
| Mar 31, 2023 | -7.21 Mn |
| Dec 31, 2022 | -100.47 Mn |
| Sep 30, 2022 | -5.72 Mn |
| Jun 30, 2022 | -6.39 Mn |
| Mar 31, 2022 | -6.96 Mn |